BD, Fujirebio Partner on Cancer Dx Assays | GenomeWeb

NEW YORK (GenomeWeb News) – Becton Dickinson and Fujirebio Diagnostics have inked a worldwide development and supply agreement for multiplex oncology diagnostic assays.

The firms said today that they will develop diagnostic products that contain Fujirebio's biomarkers that will run on BD's multiplex testing platform. Initial efforts will focus on the ovarian cancer biomarker HE4, which is cleared by the Food and Drug Administration for monitoring the progression or recurrence of epithelial ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.